University of Texas System

Other

Houston Pharmaceuticals, Inc.

Albert Einstein College of Medicine

Insmed Incorporated

Aronex Pharmaceuticals, Inc.

Priebe, Waldemar

Przewloka, Teresa

Fokt, Izabela

Skibicki, Piotr

Krawczyk, Marta

Perez-soler, Roman

Grynkiewicz, Grzegorz

Roman Perez-Soler

Waldemar Priebe

Abdul R Khokhar

Gabriel Lopez-Berestein

Teresa Przewloka

Piotr Skibicki

Izabela Fokt

Marta Krawczyk

Grzegorz Grynkiewicz

Yiyu Zou

Yi-He Ling

Izabella Fokt

Kapil Mehta

Charles D Kelman

Vladimir Malinin

Walter Perkins

Jin K Lee

Robert P Lenk

Frank G Pilkiewicz

Waldeman Priebe

Krzysztof Dziewiszek

Alan C Hayman

Jonathan B Chaires

Alan C Hayman, Deceased

Steven M Sugarman

Kenneth R Poirot

Insook Han

Robert Lenk

Teresa Prezewloka

One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml. Another aspect of the invention relates to lipid-complexed platinum compound compositions where the concentration of the platinum compound is greater than about 1.2 mg/ml.

Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally

The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy

The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3' of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4&#x2032; of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.

Anthracycline antibiotics and methods of treating cancer using the same

This invention provides an aqueous/t-butanol solvent-system, facile reconstitute, submicron-reconsitiute preliposome-lyophilaye and method of its preparation and use. In one embodiment this entails a modified method for the preparation of a submicron and stable liposome formulation of the non-cross-resistant anthracycline Annamycin is described. The optimal lipid composition was DMPC:DMPG at a 7:3 molar ratio and the optimal lipid:drug weight ratio 50:1. The selected formulation is a preliposome lyophilized powder that contains the phospholipids, Annamycin, and 1.7 mg Tween 20 per mg of Annamycin. The liposome suspension is obtained on the day of use by adding normal saline at 37&#xb0; C. (1 ml per mg Annamycin) and hand-shaking for one minute. The presence of Tween 20 is essential in shortening the reconstitution step (from &#x3e;2 hours to 1 minute), avoiding the early formation of free drug crystals, and reducing the median particle size (from 1.5 &#x3bc;m to 0.15-0.20 &#x3bc;m) without destruction of the liposome vesicles. The chemical stability of the preliposome powder at room temperature was &#x3e;3 months and the chemical and physical stability of the liposome suspension at room temperature &#x3e;24 hours. The in vitro cytotoxicity of the formulation was equivalent to that prepared by the standard evaporation method. The results of the study indicate that small amounts of surfactant may be used to enhance the reconstitution step and reduce the liposome size of lyophilized liposome formulations of lipophilic drugs.

Submicron liposome suspensions obtained from preliposome lyophilizates

The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.

Gene therapy of tumors using non-viral delivery system

Methods and compositions for the manufacture of C-3' and C-4&#x2032; anthracycline antibiotics

Antitumor compositions are disclosed, as well as methods of preparing the compositions and methods of using them to inhibit tumor growth in mammals. The invention can take advantage of intraliposomal conversion of a platinum complex having the formula

Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes

The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-based DNA alkylators.

Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents

The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3&prime; of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4&prime; of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.

Methods and compositions for the manufacture of C-3&prime; and C-4&prime; anthracycline antibiotics

A method of evaluating the chemosensitivity of a tumor to an anti-tumor agent in vivo is provided. The method comprises extracting a portion of a tumor from a human host and inserting the portion of the tumor into an immunodeficient mouse. The tumor portion is permitted to grow to a minimum preselected size to form a test tumor. An amount of an anti-tumor agent is administered to the immunodeficient mouse sufficient to determine whether the anti-tumor agent is effective in treating the test tumor. The anti-tumor activity of the anti-tumor agent on the test tumor is assessed.

In vivo chemosensitivity screen for human tumors

The present invention is directed towards a surgical system and method of use for treating and removing unwanted tissue, preferably from an organ or other internal part of a patient. The system includes a cryosurgical component for first freezing the unwanted living tissue by forming an ice mass which completely encompasses the unwanted living tissue and means for treating the cryogenically-treated tissue and then removing the tissue while it remains in a frozen state. In one embodiment, an ultrasonic device is used to ultrasonically vibrate the cryogenically-treated tissue to break apart the frozen tissue and the frozen broken-up pieces of tissue are removed using a technique, such as an aspiration process.

Cryogenic surgical system and method of use in removal of tissue

The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In doxorubicin (DOX) sensitive cell lines, they are at least as cytotoxic as DOX and in some cases more so. Many of these 4&prime;- and 6&prime;-fluorinated anthracyclines are more effective against multidrug-resistant tumors than was DOX, and/or have greater effectiveness than DOX against DOX sensitive cells. The compounds of this invention also have anti-amyloidogenic effects and the use of these compounds in the treatment of Alzheimer's disease is contemplated.

Methods and compositions for the manufacture of halogenated anthracyclines with increased antitumor activity, other anthracyclines, halogenated sugars, and glycosyl donors

Growing community of inventors

New York, NY, United States of America

Roman Perez-Soler